SLU-PP-332 vs O-304: Exercise Mimetic Comparison

SLU-PP-332 vs O-304: Exercise Mimetic Comparison

SLU-PP-332 and O-304 Introduction

SLU-PP-332 works through estrogen related receptors activation, specifically ERRα, O-304 through AMPK activation pathways, but As of available research data, O-304 (also known as ATX-304, developed by Amplifier Therapeutics) has progressed to Phase IIa human clinical trials, while SLU-PP-332 remains in preclinical research stages with no published human trial data.

Molecular Structure and Chemical Data Comparison

SLU-PP-332 is a small molecule synthetic ERRα agonist developed at Louis University, research published in ACS Chem Biol shows its potent activation of estrogen related receptors. The compound has good oral bioavailability, suitable for research use.

O-304 (clinically designated ATX-304 by its developer Amplifier Therapeutics) is a pan-AMPK activator with a characterized salt formulation. Both compounds target energy metabolism pathways but differ in chemical structure and upstream signaling: SLU-PP-332 acts at the transcription factor level (nuclear ERR activation), while O-304 works via enzyme signaling (cytoplasmic AMPK activation).

SLU-PP-332 is stable under normal lab conditions and has consistent pharmacokinetic profile in preclinical studies.

SLU-PP-332 vs O-304 Research Areas

Cardiovascular Safety — Resting Heart Rate: Preclinical research in mice has identified a notable finding with SLU-PP-332: the compound produced a measurable increase in resting heart rate. This cardiovascular signal is considered a significant research variable for ERR agonists and represents an area requiring further investigation before human trial applications can be considered. No equivalent cardiovascular signal has been reported in O-304 (ATX-304) Phase IIa trial data.

Mechanism of Action: SLU-PP-332 vs O-304

Clinical Research and Study Results Comparison

Safety profile of slu pp 332 looks good in preclinical studies with no significant adverse effects in mice models.

O-304 research data is limited in the literature, more research is needed to establish efficacy and safety profiles.

Future Research Directions for Both Compounds

Combination therapy studies are emerging, particularly on how slu pp 332 can complement existing diabetes treatments or lifestyle interventions. Long term effects on mitochondrial function and cellular respiration need to be investigated.

Regulatory pathways for both compounds need to be considered as experimental therapeutics. The risk of misuse as performance-enhancing agents requires appropriate regulatory framework for clinical development and therapeutic use.

Availability and Access: SLU-PP-332 vs O-304

Both slu pp 332 and O-304 are in research phase and not FDA approved for clinical use. Access is limited to research institutions and qualified investigators conducting research on exercise mimetics and metabolic health interventions.

SLU-PP-332 is available through research peptide suppliers but requires quality verification and compliance with institutional research protocols. The compound is an investigational drug and requires proper oversight and adherence to research ethics guidelines.

Cost for research use depends on compound complexity and synthesis requirements. As research progresses and manufacturing scales up, availability and cost may improve for qualified research applications.

Summary and Conclusion

O-304 is another approach through AMPK activation but limited research data makes comparison challenging.

References

• Billon C, et al. ACS Chem Biol. 2023.
• Welch R, Banerjee S, et al. Preclinical studies of slu pp 332 in diet induced obesity models.
• Xu et al. 2023. Mitochondrial biogenesis and exercise mimetic effects of pp 332.
• Clinical trial databases for exercise mimetics research and safety studies.
• Regulatory documents for experimental therapeutics classification and development pathway for metabolic interventions. and O-304 Introduction

SLU-PP-332 works through estrogen-related receptors activation, specifically ERRα, O-304 through AMPK activation pathways, but O-304 (ATX-304) has progressed further in clinical development than SLU-PP-332, having completed Phase IIa human trials while SLU-PP-332 remains in preclinical research stages.